The tropical disease medication most international travelers need before departure is an antimalarial drug — and the one you choose matters more than you might think. The CDC recommends four antimalarial medications for travelers: atovaquone-proguanil (sold as Malarone), doxycycline, mefloquine, and tafenoquine. All four are equally effective when taken correctly, reducing malaria risk by approximately 90 percent. But they differ sharply in cost, side effects, and how far in advance you need to start taking them — details that can make or break your protection, especially if you are managing other medications for conditions like dementia or cognitive decline.
Malaria is not some distant, abstract threat. In 2024, the World Health Organization recorded 282 million malaria cases and 610,000 deaths globally, an increase of roughly 9 million cases over the prior year. Africa carries 94 percent of those cases and 95 percent of deaths, with children under five accounting for three-quarters of African malaria fatalities. But travelers from the United States and Europe are far from immune — cases among returning travelers tick upward every year, and the cognitive symptoms of severe malaria, including confusion, seizures, and delirium, can mimic or worsen existing neurological conditions. Beyond antimalarials, this article covers the travel vaccines you may need in 2026, including the newly approved chikungunya vaccine, the timing that makes or breaks vaccine effectiveness, and why layered prevention — not any single pill — is the real key to staying safe abroad.
Table of Contents
- Which Tropical Disease Medications Do You Need Before International Travel?
- Comparing Cost and Side Effects of Antimalarial Drugs
- Travel Vaccines You May Need in 2026
- Why Timing Your Medications and Vaccines Makes or Breaks Protection
- Drug Resistance and the Limits of Prevention
- Dengue — The Major Threat Without a Traveler Vaccine
- What the Next Few Years May Bring
- Conclusion
- Frequently Asked Questions
Which Tropical Disease Medications Do You Need Before International Travel?
The answer depends entirely on where you are going. If your destination falls within a malaria-endemic zone — large portions of Sub-Saharan Africa, South and Southeast Asia, Central America, and parts of South America — you need a prescription antimalarial. The CDC’s four recommended options are atovaquone-proguanil, doxycycline, mefloquine, and tafenoquine. None of them are interchangeable in practice. Atovaquone-proguanil is the best choice for last-minute travelers because it can be started just one to two days before entering a malaria zone and stopped one week after leaving. Doxycycline and mefloquine, by contrast, must be started one to two weeks before travel and continued for a full four weeks after you return.
This distinction is not trivial. A retired couple planning a three-week safari in Kenya will have very different needs than a caregiver flying to Lagos on short notice to help a family member. If you are already managing a daily medication regimen for Alzheimer’s disease or another form of dementia, the timing and drug interaction profile of your antimalarial matters. Mefloquine, for instance, has well-documented neuropsychiatric side effects — vivid dreams, anxiety, and in rare cases, psychosis — that make it a poor fit for anyone with an existing cognitive or psychiatric condition. Your travel medicine provider needs to know your full medication list before writing a prescription. For destinations where malaria is not a risk but other mosquito-borne diseases circulate, you may not need a daily prophylactic medication, but you will almost certainly need vaccines and rigorous personal protection measures. Dengue, chikungunya, and Japanese encephalitis all require different strategies, and no single pill covers everything.
Comparing Cost and Side Effects of Antimalarial Drugs
Cost is a real barrier, and the price differences between antimalarials are staggering. For a typical 30-day trip, the median cost of mefloquine runs about $105.60, doxycycline falls between $121 and $182, and atovaquone-proguanil — the most convenient and best-tolerated option — costs roughly $261.90. Making matters worse, prices can vary up to tenfold between pharmacies for the same drug. A traveler who fills a prescription at a hospital outpatient pharmacy may pay several times what they would at an independent pharmacy or through a mail-order service. It pays to shop around. Doxycycline is typically the cheapest option, but it comes with a significant catch: pronounced sun sensitivity.
If your travel involves beaches, outdoor markets, or safari drives under equatorial sun, doxycycline can cause painful, blistering sunburns even with sunscreen. It also causes gastrointestinal irritation if taken on an empty stomach. Atovaquone-proguanil is the best-tolerated antimalarial, with fewer reported side effects across clinical trials, but its price puts it out of reach for some travelers, particularly those on fixed incomes or managing the financial burden of long-term dementia care. However, if cost drives you toward mefloquine, proceed with caution. While mefloquine is affordable and conveniently dosed once weekly rather than daily, its neuropsychiatric side effects — including depression, paranoia, and disturbing dreams — are not rare anecdotes. For individuals already living with mild cognitive impairment or early-stage dementia, these effects can be disorienting and frightening. Any new confusion or behavioral change during travel may be mistakenly attributed to disease progression rather than a medication side effect, delaying appropriate care.
Travel Vaccines You May Need in 2026
antimalarials address only one piece of the tropical disease puzzle. Several destinations now require or strongly recommend vaccines that did not exist or were not widely available a few years ago. The yellow fever vaccine remains required for entry to many countries in Africa and South America, and a single dose is now considered valid for life — no booster needed. This is especially relevant in early 2026, with increased yellow fever cases reported in Colombia.
One of the most significant developments is the FDA’s approval of the chikungunya vaccine, VIMKUNYA, in February 2025 for adults and adolescents aged 12 and older. Chikungunya causes debilitating joint pain that can persist for months or years, and active outbreaks are underway in Cuba, Suriname, Bolivia, the Seychelles, and Mexico’s Quintana Roo region. For older travelers or those with existing joint or mobility issues common in dementia patients, chikungunya infection can be particularly devastating, leading to prolonged immobility that accelerates cognitive and physical decline. Other vaccines to discuss with your travel medicine provider include the typhoid vaccine, recommended for travel to parts of Asia, Africa, the Caribbean, and Central and South America, and the Japanese encephalitis vaccine, recommended for travelers spending one month or more in endemic areas during transmission season. Japanese encephalitis is particularly relevant for brain health: the virus causes inflammation of the brain, and survivors frequently experience lasting cognitive deficits, personality changes, and motor impairments that overlap with dementia symptoms.
Why Timing Your Medications and Vaccines Makes or Breaks Protection
The single most common mistake travelers make is waiting too long to see a travel medicine provider. Vaccines need time to generate an immune response, and the CDC recommends getting vaccinated four to six weeks before departure. A yellow fever vaccine administered the day before your flight offers virtually no protection. The same principle applies to antimalarials that require a loading period — mefloquine must be started at least two weeks before entering a malaria zone to reach adequate blood levels and to identify any intolerable side effects while you can still switch medications. The tradeoff between early planning and last-minute flexibility is real.
Atovaquone-proguanil’s one-to-two-day lead time makes it ideal for emergency or unplanned travel, but that convenience comes at a higher price. Doxycycline and mefloquine cost less but demand more advance planning. For caregivers who may need to travel internationally on short notice — say, a family emergency involving a relative abroad — having a travel medicine consultation already completed and a prescription for atovaquone-proguanil on hand can save critical days. If you or a family member with dementia is traveling, build medication management into the trip planning from the start. Antimalarials must be taken on schedule, and missed doses can leave dangerous gaps in protection. Pill organizers, phone alarms, and caregiver reminders are not optional — they are as essential as the medication itself.
Drug Resistance and the Limits of Prevention
No antimalarial drug is 100 percent effective, and the global picture is getting more complicated. Antimalarial drug resistance has been confirmed or suspected in at least eight African countries, a trend the WHO flagged as a growing concern in its 2025 World Malaria Report. This does not mean antimalarials are useless in those regions — they still significantly reduce risk — but it does mean that medication alone is not enough. Layered prevention is essential. The CDC recommends combining antimalarial drugs with personal protective measures: DEET-based insect repellent applied to exposed skin, long sleeves and pants during peak mosquito hours at dawn and dusk, and sleeping under insecticide-treated bed nets.
These measures sound basic, but compliance drops sharply during travel, especially in hot climates. A traveler who faithfully takes atovaquone-proguanil every morning but skips repellent during an evening outdoor dinner is gambling with a 10 percent failure window. For travelers with cognitive impairment, compliance with these layered measures is an even greater challenge. A person with moderate dementia may not remember to reapply repellent, may resist wearing long sleeves in tropical heat, or may remove a bed net during the night. Caregivers must anticipate these scenarios and plan accordingly — permethrin-treated clothing that does not require reapplication, for example, can eliminate one variable from the equation.
Dengue — The Major Threat Without a Traveler Vaccine
Dengue remains one of the most frustrating gaps in travel medicine. The 2024 to 2025 dengue season was the most active on record, with major outbreaks in Puerto Rico, Honduras, Nicaragua, Costa Rica, and Mexico’s Yucatán Peninsula. Despite this, no dengue vaccine is currently approved for U.S. travelers visiting, rather than living in, endemic areas.
The existing vaccine, Dengvaxia, is only approved for individuals aged 9 to 16 who have had a prior confirmed dengue infection and live in endemic areas. This means that if your travel takes you to a dengue hotspot, your only protection is avoiding mosquito bites. That makes personal protective measures — repellent, clothing, nets — not merely supplemental but your entire defense. For older adults, dengue poses heightened risks: the severe form, dengue hemorrhagic fever, can cause organ damage, and the high fevers and dehydration associated with even mild dengue can trigger delirium in people with underlying cognitive vulnerability.
What the Next Few Years May Bring
The approval of the chikungunya vaccine in 2025 marked a genuine milestone — the first new mosquito-borne disease vaccine for travelers in years. Research pipelines include next-generation malaria vaccines building on the WHO-recommended RTS,S and R21 vaccines now being deployed in African children, as well as continued work on broader dengue vaccines that could eventually protect travelers without prior infection. For the dementia care community, these developments matter.
As global travel becomes more accessible and families become more geographically dispersed, the number of older adults and cognitively impaired individuals crossing into tropical disease zones will only grow. Meanwhile, 47 countries have now been certified malaria-free by the WHO, a reminder that progress is real even as new challenges emerge. The smartest approach remains the simplest: see a travel medicine specialist early, take your medications as prescribed, protect against bites, and make sure everyone in your travel party — including those who may not be able to advocate for themselves — has a clear, managed prevention plan.
Conclusion
International travel to tropical regions demands more than a passport and a plane ticket. The right antimalarial medication, chosen in consultation with a travel medicine provider who understands your full medical history, is the single most important pharmaceutical step you can take. Whether that means affordable mefloquine started weeks in advance, convenient but pricier atovaquone-proguanil for a last-minute trip, or doxycycline with a good sunscreen strategy, the choice should be individualized — never defaulted to whatever is easiest to prescribe. Beyond antimalarials, stay current on recommended and required vaccines, especially the newly available chikungunya vaccine for destinations with active outbreaks.
Plan four to six weeks ahead when possible. Layer your prevention with repellent, protective clothing, and bed nets. And if you are traveling with or caring for someone with dementia or cognitive impairment, build medication compliance and bite prevention into the daily care routine with the same rigor you apply at home. The diseases are real, the medications work, and the planning is what ties it all together.
Frequently Asked Questions
Can I take antimalarial medication if I am already on Alzheimer’s drugs like donepezil or memantine?
In most cases, yes, but you must consult both your neurologist and a travel medicine specialist. Atovaquone-proguanil and doxycycline have relatively few drug interactions with common dementia medications, but mefloquine’s neuropsychiatric side effects make it a poor choice for individuals with cognitive conditions. Always bring a complete medication list to your travel health appointment.
How far in advance should I see a travel medicine doctor before an international trip?
The CDC recommends four to six weeks before departure. This allows time for vaccines to build immunity and for antimalarial medications that require a loading period, such as mefloquine, to reach effective blood levels. If you are traveling on shorter notice, atovaquone-proguanil can be started just one to two days before entering a malaria zone.
Is there a vaccine for dengue that I can get before traveling?
Not for most travelers. No dengue vaccine is currently approved for U.S. travelers visiting endemic areas. The existing vaccine, Dengvaxia, is only for people aged 9 to 16 with prior confirmed dengue infection who live in endemic regions. Your only protection as a visitor is avoiding mosquito bites through repellent, clothing, and nets.
Do I still need antimalarial medication if I am only visiting a major city?
It depends on the city and country. Some urban areas in endemic countries have low or no malaria transmission, while others remain high-risk. The CDC’s destination-specific recommendations should guide your decision — do not assume that a city setting means no risk.
What should I do if I develop a fever after returning from a tropical destination?
Seek medical attention immediately and tell the provider where you traveled. Malaria symptoms can appear as late as several weeks after exposure, even if you took prophylactic medication. Rapid diagnosis and treatment are critical, as severe malaria can progress quickly and its neurological symptoms — confusion, seizures, impaired consciousness — can be especially dangerous for individuals with pre-existing cognitive conditions.
